High-dose idarubicin in combination with Ara-C in patients with relapsed or refractory acute lymphoblastic leukemia: a pharmacokinetic and clinical study

@article{Tedeschi2006HighdoseII,
  title={High-dose idarubicin in combination with Ara-C in patients with relapsed or refractory acute lymphoblastic leukemia: a pharmacokinetic and clinical study},
  author={Alessandra Tedeschi and Marco Montillo and Elena Strocchi and Anna Maria Cafro and Elisabetta Tresoldi and Liliana Intropido and Michele Nichelatti and Laura Marbello and Claudia Barat{\'e} and Carlo Maurizio Camaggi and Enrica Morra},
  journal={Cancer Chemotherapy and Pharmacology},
  year={2006},
  volume={59},
  pages={771-779}
}
High dose (HD) Ara-C combined with a single HD idarubicin dose (IDA) is an efficient and safe salvage regimen for patients with refractory or relapsed acute lymphoblastic leukemia as indicated by phase II studies. No data are available on the pharmacokinetics of IDA after a rapid HD intravenous infusion. An open phase II pharmacokinetic and clinical study was performed to evaluate antileukemic efficacy, IDA pharmacokinetics and to investigate the presence of IDA and its reduced metabolite… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-9 of 9 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 36 references

Similar Papers

Loading similar papers…